Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $23.9 in the prior trading day, Intellia Therapeutics Inc (NASDAQ: NTLA) closed at $25.93, up 8.49%. In other words, the price has increased by $8.49 from its previous closing price. On the day, 5.51 million shares were traded. NTLA stock price reached its highest trading level at $26.319 during the session, while it also had its lowest trading level at $24.2307.
Ratios:
Our goal is to gain a better understanding of NTLA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.19 and its Current Ratio is at 5.19. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.11.
On April 21, 2025, Wolfe Research Upgraded its rating to Outperform which previously was Peer Perform but kept the price unchanged to $21.
On March 05, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.H.C. Wainwright initiated its Buy rating on March 05, 2025, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 01 ’25 when Schultes Birgit C sold 31 shares for $17.38 per share. The transaction valued at 539 led to the insider holds 105,184 shares of the business.
Dube Michael P sold 1,871 shares of NTLA for $32,518 on Oct 01 ’25. The VP, Chief Accounting Officer now owns 55,266 shares after completing the transaction at $17.38 per share. On Aug 20 ’25, another insider, CHASE WILLIAM J, who serves as the Director of the company, bought 100,000 shares for $10.03 each. As a result, the insider paid 1,003,000 and bolstered with 134,693 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 2783504896 and an Enterprise Value of 2426444800. For the stock, the TTM Price-to-Sale (P/S) ratio is 52.66 while its Price-to-Book (P/B) ratio in mrq is 3.82. Its current Enterprise Value per Revenue stands at 45.906 whereas that against EBITDA is -4.835.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.40, which has changed by 0.13918018 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $26.99, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is 75.90%, while the 200-Day Moving Average is calculated to be 137.17%.
Shares Statistics:
The stock has traded on average 5.64M shares per day over the past 3-months and 7622570 shares per day over the last 10 days, according to various share statistics. A total of 105.33M shares are outstanding, with a floating share count of 101.56M. Insiders hold about 5.39% of the company’s shares, while institutions hold 87.73% stake in the company. Shares short for NTLA as of 1759190400 were 29739035 with a Short Ratio of 5.27, compared to 1756425600 on 27737890. Therefore, it implies a Short% of Shares Outstanding of 29739035 and a Short% of Float of 31.379997999999997.
Earnings Estimates
The performance of Intellia Therapeutics Inc (NTLA) in the stock market is under the watchful eye of 20.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.98, with high estimates of $0.04 and low estimates of -$1.49.
Analysts are recommending an EPS of between -$2.67 and -$4.74 for the fiscal current year, implying an average EPS of -$4.11. EPS for the following year is -$4.01, with 23.0 analysts recommending between -$2.37 and -$5.05.
Revenue Estimates
A total of 24 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $210M, while the lowest revenue estimate was $30.87M, resulting in an average revenue estimate of $61.91M. In the same quarter a year ago, actual revenue was $57.88M
